Other news to note for March 10, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abbvie, Aim Immunotech, Algernon, Allergan, Alopexx Oncology, Arcturus, Beijing Shenogen, Beroni, Biocartis, Bionomics, Bristol-Myers Squibb, Cel-Sci, Cocrystal, Cyclica, Domain, Epivax, Generex, Gilead Sciences, Harbour Biomed, Heat Biologics, Humanigen, Iktos, Innovation, Inovio, Komipharm, Nascent, Neuren, Oncosec Medical, Royalty, Shionogi, SRI International, Stada Arzneimittel, Takeda, Tetra, TFF, Xoma, Xphyto, Zydus Cadila.

Regulatory front for March 10, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: FDA, FTC.

Appointments and advancements for March 10, 2020

New hires and promotions in the biopharma industry in Asia-Pacific, including: Shenzhen Hepalink Pharmaceutical.

Clinical data for March 3-9, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Bioarctic, Chugai, Cytodyn, Eisai, Innovent Biologics, Oncolys.

Regulatory actions for March 3-9, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Acadia, Ascentage, Immutep, Neuren, Zydus Cadila.

No Comments